YYou read the web publishing of the Newsletter of Stat Health Technology, our guide on how technology transforms life sciences. Register to get it Delivered in your reception box every Tuesday and Thursday.
Buried in a Project budget disclosed From the Trump administration is a request that can alarm (or elevate?) Observers of health technologies. The Administration proposes to create a new office of the director of technology within the Federal Health Department which would house the Deputy Secretary of Technological Policy, the IT regulator of the Ministry of the Ministry and a “Chief Information Office”. Under the proposal, ASTP would be funded with $ 9 million, compared to the appropriate $ 66 million in the 2023 budget.
Although this financing document is preliminary and likely to be ignored by the congress (as the legislators have regularly done in the past), it is remarkable in the light of the whispers that a reshuffle can happen to ASTP.
Learn more about the budget here And contact us if you know more.
The radiology network brings together an AI company
Radnet, which manages a network of nearly 400 radiology imaging centers, announced this week an agreement to acquire ICAD, a developer of an AI breast cancer screen, for $ 103 million. Radnet has made a series of acquisitions in recent years as it seeks to strengthen its AI capacities.
Radnet’s desire to bet big on AI is notable given a lukewarm response on the market so far. Radiology products represent more than three -quarters of the AI devices eliminated by the Food and Drug Administration, but as Katie Palmer’s reports from StatAdoption by service providers can be a jack for autonomous developers. The reimbursement is not guaranteed and even then, the economy can be difficult for the practices that wish to adopt. An AI used alongside the reading of a technician must bring you money, make your practice more effective or considerably improve the results. Given its new technology, evidence of the advantages are still becoming. Read more here
The test manufacturer used by Unitedhealth can settle with the doj
Scientist proposed to pay The Ministry of Justice nearly $ 30 million to settle federal allegations on health care fraud linked to its test of peripheral arteries, Quantaflo. Semler revealed the preliminary agreement in A dry file Tuesday. The agreement would resolve an investigation to find out if the federal health programs have paid inappropriate complaints according to the use of quantaflo, which would violate the law on false complaints.
A Stat survey Last year revealed that Unitedhealth Group, which has the largest advantage drug insurer in the country, stimulated Medicare reimbursements using Quantaflo to filter patients for vascular diseases. Learn more about Lizzy Lawrence from Stat here
Spending on remote monitoring is increasing
The Peterson Center on Healthcare this week published a report Examine remote monitoring technologies, including new complaint data. The above graph shows an increasing use of remote physiological monitoring codes, which providers use to invoice patients with devices such as blood pressure cottons and to examine data and communicate with patients on this subject. RPM regime expenditure in the traditional Medicare rose from $ 6.8 million in 2019 to 194 million dollars in 2023.
The Center notes that there are use cases where remote monitoring has a high clinical impact, as if to help people stabilize high blood pressure. However, the report notes that many advantages of surveillance are obtained in a few months and a third of registrants using RPM are monitored for 7 months or more. The report suggests duration limits for monitoring and limiting payment to conditions where monitoring shows value. Last fall, a federal childcare dog from the Department of Health published a report Warning of fraud potential by providers offering remote monitoring to patients.
The Télésanté program saves 68 carbon steaks
In A new paper in the NEJM catalystResearchers from the Ministry of Veterans Affairs estimate that a diabetes care program based on remote charts which recruited 576 patients “prevented more than 200,000 driving miles, saving around $ 20,000 in petrol costs for patients and 82 metric tonnes of carbon dioxide program compared to equivalent care in person.” Elsewhere, researchers believe that the reduction of carbon dioxide for each veteran “would be equal to carbon emissions associated with the production of more than 68 beef steaks for human consumption”.
I’m too hungry to check the calculations.
So how do you click on marketing your therapeutic migraine?
As I noted briefly on Tuesday, click on Therapeutics this week received Classing of the FDA for CT-132, a new digital treatment based on smartphones (an application) which aims to reduce the number of days that people experience migraines.
- Data: In a randomized control trial, people who received the processing application reported a reduction of approximately three days without migraines per month compared to the control group which used a dummy application, which experienced a reduction of approximately two days.
- The problem for CT-132 is similar to the Rejoyn problem, the depression treatment developed jointly by Otsuka and click CLearn by the FDA last year: It is very difficult to earn money on these clinical applications when marketed as medicines. Insurance reimbursement is nonexistent, and there is little evidence that a critical mass of people pocket.
- In an email, Rich Denunzio, the Click Commercial Director, stressed data showing that the application offers advantages for patients who continue to suffer from migraines despite CGRP therapy, which, according to him, opens the door to “integrated solutions with CGRP manufacturers” FDA advice project Around software related to the use of prescription drugs.
The new partners of Vely and a Lilly ML agreement
- In truth, the alphabet health technology company today announcement that Nashbio,, University of Oxfordand the Intra-muros of NIH for Alzheimer’s disease and related dementias New customers use its workbench product to help store and analyze data.
- Bighat BiosciencesWho uses automatic learning to hunt new antibodies, announced that he was working with Eli Lilly On up to two candidates for chronic diseases, as well as to advance an internal conjugate of antibodies for gastrointestinal cancers with the support of Lilly. As part of the partnership, Lilly invests in Bighat, with Cripple And Samsung VenturesBringing the start of the startup of the startup to more than $ 120 million.